IM Cannabis (IMCC) Stock Price, News & Analysis

Company Overview

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners.

Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.

Key Stats

• Today's Range: $1.90 to $1.92
• 50-Day Range: $1.79 to $3.55
• 52-Week Range: $1.29 to $7.12
• Volume: 1,672 shs
• Average Volume: 112,354 shs
• Market Capitalization: $9.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IM Cannabis Stock Analysis - MarketRank™

IM Cannabis scored higher than 18% of companies evaluated by MarketBeat, and ranked 887th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for IM Cannabis.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IM Cannabis is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IM Cannabis is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IM Cannabis has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of IM Cannabis has been sold short.

Short Interest Ratio / Days to Cover

IM Cannabis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IM Cannabis has recently decreased by 49.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IM Cannabis does not currently pay a dividend.

Dividend Growth

IM Cannabis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.43% of the float of IM Cannabis has been sold short.

Short Interest Ratio / Days to Cover

IM Cannabis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IM Cannabis has recently decreased by 49.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

IM Cannabis has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for IM Cannabis this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for IMCC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IM Cannabis insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 7.68% of the stock of IM Cannabis is held by institutions.

IMCC Stock Analysis - Frequently Asked Questions

How have IMCC shares performed this year?

IM Cannabis' stock was trading at $2.33 at the beginning of 2025. Since then, IMCC shares have decreased by 15.5% and is now trading at $1.97.

How were IM Cannabis' earnings last quarter?

IM Cannabis Corp. (NASDAQ:IMCC) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07. The firm earned $9.21 million during the quarter, compared to analyst estimates of $12.88 million. IM Cannabis had a negative trailing twelve-month return on equity of 59.80% and a negative net margin of 4.19%.

When did IM Cannabis' stock split?

Shares of IM Cannabis reverse split on Friday, July 12th 2024.The 1-6 reverse split was announced on Friday, July 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are IM Cannabis' major shareholders?

Top institutional shareholders of IM Cannabis include Heron Bay Capital Management (1.95%).

How do I buy shares of IM Cannabis?

Shares of IMCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IM Cannabis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IM Cannabis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), GE Aerospace (GE) and AppLovin (APP).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/14/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCC
• CIK: 1792030
• Web: www.imcannabis.com
• Phone: 972-54-433-1111
• Fax: N/A
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.72 million
• Net Margins: -4.19%
• Pretax Margin: -4.55%
• Return on Equity: -59.80%
• Return on Assets: -5.15%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 0.72
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $39.44 million
• Price / Sales: 0.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.03 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 5,250,000
• Free Float: N/A
• Market Cap: $10.34 million
• Optionable: Not Optionable
• Beta: 2.19